BCM
ENGN icon

BML Capital Management’s enGene Therapeutics ENGN Stock Holding History

BML Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5M Buy
+6,669,908
New +$27.2M 6.55% 3

Other funds holding ENGN

PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
FA
Fountainhead AM Warren, New Jersey $135M AUM 24.26% 1-Year Est. Return
PP
PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

BML Capital Management's ENGN Position: Q2 2026 in Review

BML Capital Management opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 6,669,908 shares worth $11.5M. The stake represents 6.55% of the portfolio and ranks #3 among its holdings.

11 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • BML Capital Management held 6,669,908 shares of enGene Therapeutics worth $11.5M as of Q2 2026.
  • enGene Therapeutics was a new BML Capital Management position in Q2 2026.
  • enGene Therapeutics made up 6.55% of BML Capital Management's portfolio in Q2 2026, its #3 holding.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on BML Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.